Clearmind Medicine Inc

Clearmind Medicine, Inc. operates as a mineral resource company, which acquires, explores, develops, and operates mineral resource assets in Canada. The company was founded on July 18, 2017 and is headquartered in Toronto, Canada.

Earnings data Q2 2024

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.

Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule. The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has applied and received approval for a voluntary delisting of its common shares from the Canadian Securities Exchange ("CSE"). The delisting from the CSE will not affect the company's listing on the NASDAQ Capital Market (the "NASDAQ"). The common shares will continue to trade on the NASDAQ under the symbol CMND.

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

New patent applications build upon Clearmind's broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted three additional patent applications under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has submitted three patent applications under the international Patent Cooperation Treaty ("PCT"), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Tel Aviv, Israel / Vancouver, Canada, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has been granted divisional patent approval by the China National Intellectual Property Administration.

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ:CMND). About Clearmind Medicine Inc. Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally.

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the closing of its previously announced definitive agreements with institutional investors for the purchase and sale of Common Shares and Pre-Funded Warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors, Common Warrants. Aggregate gross proceeds to the Company from both transactions were approximately $2.4 million.

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

TEL AVIV, ISRAEL / VANCOUVER, CANADA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of Common Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors Common Warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.4 million.

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

Clearmind Medicine (NASDAQ: CMND ) stock is slipping on Thursday after the psychedelics pharmaceutical company's shares underwent a major rally on Wednesday. The news that sent shares of CMND stock higher yesterday was a meeting with the Food and Drug Administration (FDA).

Why Is Clearmind Medicine (CMND) Stock Down 24% Today?

Shares of Clearmind Medicine (NASDAQ: CMND ) stock, which aims to use psychedelics to treat mental health, jumped overnight. This after it completed a meeting with the Food and Drug Administration (FDA) on its trial of a compound to treat Alcohol Use Disorder.

Why Is Clearmind (CMND) Stock Up 40% Today?

Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has completed a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss  the Company's clinical trial of its proprietary MEAI-based, CMND-100 compound, for the treatment of Alcohol Use Disorder treatment (AUD) using its novel psychedelic- based therapy.

Clearmind Medicine Completed Type A Meeting with the FDA

The collaboration included filing six different US patent applications with the United States Patent and Trademark Office to protect novel combinations of psychedelics with SciSparc's PEA

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been Cured Tel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that on December 12, 2023 it received a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires the Company's common shares to maintain a minimum bid price of $1.00 per share.

Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

Clearmind Medicine Inc. (NASDAQ:CMND) is on the move this week after favourable stock market news. The company dedicates its resources to discovering a cure for cocaine addiction.

Clearmind Medicine Inc (CMND) is the goose that got cooked – trade carefully

Following another soft opening on Wall Street, Clearmind Medicine (NASDAQ: CMND ) provided an optimistic contrast thanks to positive trial results. Specifically, the biotechnology firm — which focuses on the discovery and development of novel psychedelic-derived therapeutics — saw encouraging advances regarding its novel treatment targeting cocaine addiction.

Why Is Clearmind Medicine (CMND) Stock Up 50% Today?

The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program

Weight loss MEAI: Clearmind Medicine's Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial

Clearmind Medicine (NASDAQ: CMND) stock price was among the best-performing in Wall Street on Thursday. The share jumped by more than 32% and reached a high of $5.37.

Clearmind Medicine (CMND) stock price is flying but risks remain

Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment

Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space

Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures

Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced it will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-30. The reverse split is being effected as part of the Company's plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing November 28, 2023.

Clearmind Medicine Announces 1-for-30 Reverse Share Split

As part of the Company's plan for recompliance, the Company's shareholders approved a reverse stock split on November 14, 2023. Tel Aviv, Israel / Vancouver, Canada, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced receipt of a Staff Delisting Determination (the "Staff Determination") from the Listing Qualifications Department of the Nasdaq Stock Market, LLC ("Nasdaq").

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance

Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on November 14, 2023 (the “Meeting”), as set out in the Company's Management Information Circular dated October 9, 2023, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at four members, the election of directors of the Company for the ensuing year, a resolution to establish and approve an omnibus equity incentive plan and a resolution approving the directors to effect a consolidation (the “Consolidation”) of  the common shares in the capital of the Company (the “Shares”) on the basis of fifty (50) pre-Consolidation Shares for one (1) post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company's board of directors at its sole discretion, in one or more tranches during the twelve (12) months immediately following the Meeting.

Clearmind Medicine Announces Shareholders Meeting Results

Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial

News for Clearmind Medicine Inc Stock (CMND)